Skip to content

CNBX PHARMACEUTICALS INC.: 10-K filed 2013-11-29

What CNBX PHARMACEUTICALS INC. reported in its annual report filed 2013-11-29 (fiscal FY 2013): 12 published measures, 37 facts as tagged in accession 0001303681-13-000105.

This filing

Form
10-K (annual report)
Filed
2013-11-29
Fiscal period
fiscal FY 2013
Accession
0001303681-13-000105 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-08-3172,755USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-08-31-105,393USD
At 2012-08-31-48,992USD
At 2011-08-31-47,340USD
At 2010-08-3159,970USD
At 2009-08-31174,950USD
At 2008-08-31289,871USD
At 2007-08-31317,329USD
At 2006-08-31144,450USD
At 2005-08-31-1,279USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-09-01 to 2013-08-31-56,401USD365
2004-09-15 to 2013-08-31-467,746USD3273
2011-09-01 to 2012-08-31-1,652USD366
2010-09-01 to 2011-08-31-107,310USD365
2009-09-01 to 2010-08-31-114,980USD365
2008-09-01 to 2009-08-31-114,921USD365
2007-09-01 to 2008-08-31-27,458USD366
2006-09-01 to 2007-08-31-23,203USD365
2005-09-01 to 2006-08-31-20,021USD365
2004-09-15 to 2005-08-31-1,800USD351

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-09-01 to 2013-08-31-27,245USD365
2004-09-15 to 2013-08-31-188,352USD3273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-09-01 to 2013-08-31100,000USD365
2004-09-15 to 2013-08-31460,895USD3273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2004-09-15 to 2013-08-31-199,788USD3273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-08-31-467,746USD
At 2012-08-31-411,345USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2004-09-15 to 2013-08-311,458USD3273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-08-31178,148USD
At 2012-08-3148,992USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-08-31362,285USD
At 2012-08-31362,285USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-09-01 to 2013-08-31100USD365
2004-09-15 to 2013-08-3111,275USD3273
2011-09-01 to 2012-08-3145USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-09-01 to 2013-08-310USD365
2004-09-15 to 2013-08-31360,895USD3273

Inspect the source

Entity
CNBX PHARMACEUTICALS INC. / CIK 0001343009
Captured
2026-09-20T07:54:32.519Z
SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))